Health Policy; Food, Drug and Cosmetic Act; Medical Research and Development
Senate Health, Education, Labor, and Pensions (HELP) Committee, Office of U.S. Senator Elizabeth Warren, National Institutes of Health (NIH)
Remy L. Brim, Ph.D. is a scientist and health care policy expert focused on strategic policy and advocacy support for clients with FDA-regulated products and activities. She is a Principal at BGR and on the firm’s Executive Board. As co-head of BGRs Health Care Practice, she helps clients effectively navigate the complex regulatory and political landscapes required to advance the discovery, development, and delivery of innovative products to patients and consumers. Her success for clients is rooted in her deep technical understanding, thoughtfulness, and commitment to sound public health policy.
Prior to joining BGR Group, Remy served as Senior FDA Policy Advisor to the Senate HELP Committee’s Ranking Member, Patty Murray (D-Wash.). In this role, she was lead negotiator and advisor for U.S. Senate Democrats on FDA medical device, prescription drug, biologic, food safety and cosmetic policy initiatives, including the 21st Century Cures Act and the FDA Reauthorization Act of 2017. She managed FDA-related policy development and relationships for the Ranking Member, both internally with Senate leadership, other Senate offices, and their House counterparts, and externally with the FDA and other governmental organizations, regulated industry companies and trade associations, patient advocacy organizations and other key stakeholders.
Previously, Remy served under Sen. Elizabeth Warren (D-Mass.), including as the Senator’s Senior Health Policy Advisor from 2015 to 2016. She managed a comprehensive health care portfolio, with emphasis on policies relevant to the biotech, medical device, and health care industries rooted in Massachusetts.
Remy earned her B.S. in Microbiology and Molecular Genetics from Michigan State University and her Ph.D. in Pharmacology from the University of Michigan Medical School, where she advanced pre-clinical research to support an investigational new drug application at the FDA for a Breakthrough-designated biologic currently under clinical investigation. Remy served as a Bioethics Post-Doctoral Fellow at the National Institutes of Health from 2011 to 2013, where she analyzed ethical issues in clinical research, public health and health care, applying frameworks from philosophy, ethics and law.